Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed, Carboplatin, and Bevacizumab in Elderly Advanced Nonsquamous NSCLC
NCT00798603Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Dec 2008
- Primary completion
- Mar 2011
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Cancer and Leukemia Group B. Primary endpoint: Progression-free Survival at 6 Months. Started Dec 2008; status: completed.
02
Drugs
pemetrexedbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00798603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00798603.